Zytiga approved in Europe for chemotherapy-naive mCRPC

As in the USA and some other countries, the European Union has now approved abiraterone acetate (Zytiga®), in combination with prednisone or prednisolone, for the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC).

This announcement came in a media release issued by Janssen-Cilag International NV — a unit of Johnson & Johnson — in Belgium late on Friday last week.

Zytiga was approved for this indication in the USA in December 2012.

3 Responses

  1. Good news. Do we (as usual) have the additional hurdle of NICE in the UK?

  2. But of course, … and similar hurdles all across Europe. NICE is simply more public and transparent in making and inforing people about its decisions than are the comparable authorities in other nations.

  3. While searching for information on this following your post, I was heartened to see that NICE has spent time assessing whether they needed to remove “men” and replace it with “people” in their scoping document. … I quote:

    ” … reference to ‘men’ was removed from remit and population and replaced with ‘people’.”

    This was to remove any potential offence to those who have undergone gender reassignment. I hope it wasn’t a long debate.

    Good to know they’re beavering away at the big stuff while folks are waiting to see if they can actually access drugs that may extend their lives. …

    I’m allowed one cynical comment a day.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: